Neubase Therapeutics Stock Beta
| NBSE Stock | USD 0.44 0.02 4.76% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
NeuBase | Beta |
NeuBase Therapeutics Company Beta Analysis
NeuBase Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current NeuBase Therapeutics Beta | 0.96 |
Most of NeuBase Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NeuBase Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for NeuBase Therapeutics is extremely important. It helps to project a fair market value of NeuBase Stock properly, considering its historical fundamentals such as Beta. Since NeuBase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NeuBase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NeuBase Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, NeuBase Therapeutics has a Beta of 0.959. This is 11.51% higher than that of the Biotechnology sector and 31.01% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
NeuBase Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeuBase Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics of similar companies.NeuBase Therapeutics is currently under evaluation in beta category among related companies.
NeuBase Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in NeuBase Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of NeuBase Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NeuBase Therapeutics' value.| Shares | Tower Research Capital Llc | 2023-12-31 | 2.4 K | Bank Of America Corp | 2023-12-31 | 804 | First Manhattan Co. Llc | 2023-12-31 | 353 | Royal Bank Of Canada | 2023-12-31 | 300 | Blackrock Inc | 2023-12-31 | 84.0 | Wells Fargo & Co | 2023-12-31 | 79.0 | Advisor Group Holdings, Inc. | 2023-12-31 | 22.0 | Pnc Financial Services Group Inc | 2023-12-31 | 21.0 | Global Wealth Management Investment Advisory, Inc. | 2023-12-31 | 12.0 | Greenlight Capital, Inc | 2023-12-31 | 136.3 K | Ubs Group Ag | 2023-12-31 | 65.7 K |
NeuBase Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, NeuBase Therapeutics is expected to follow.
NeuBase Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (5.67 M) | ||||
| Shares Outstanding | 3.75 M | ||||
| Shares Owned By Insiders | 13.37 % | ||||
| Shares Owned By Institutions | 12.68 % | ||||
| Number Of Shares Shorted | 24.46 K | ||||
| Price To Earning | (4.17) X | ||||
| Price To Book | 0.18 X | ||||
| EBITDA | (32.49 M) | ||||
| Net Income | (33.78 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 6 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (29.01 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (18.60) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 1.58 M | ||||
| Total Asset | 32.69 M | ||||
| Retained Earnings | (102.74 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 4.14 M | ||||
| Current Liabilities | 1.6 M | ||||
| Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out NeuBase Therapeutics Piotroski F Score and NeuBase Therapeutics Altman Z Score analysis. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.